Tyrosine phosphatase inhibition attenuates early brain injury after subarachnoid hemorrhage in rats.

Abstract

PURPOSE:

Sodium orthovanadate (SOV) is a representative tyrosine phosphatase inhibitor and has been shown to ameliorate neuronal injury in cerebral ischemia. We hypothesized that tyrosine phosphatase inhibition by SOV might attenuate early brain injury after subarachnoid hemorrhage (SAH) in this study.

METHODS:

The endovascular perforation model of SAH was produced and animals were randomly assigned to sham-operated rats, saline-treated (vehicle), and 10 mg/kg of SOV-treated SAH rats. Drugs were injected intraperitoneally immediately after SAH induction. Neurological score and brain water content (BWC) were assessed at 24 h after SAH. Cell injury was studied by terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling (TUNEL) at 24 h after SAH.

RESULTS:

Severity of SAH and mortality in SOV-treated rats was similar to that of the saline group. SOV significantly decreased BWC and improved neurological score at 24 h after SAH compared with the saline group. SOV decreased TUNEL-positive cells at 24 h after SAH compared with the saline group.

CONCLUSIONS:

These data suggest that tyrosine phosphatase inhibition by SOV ameliorates early brain injury after SAH.

• Authors: Yu Hasegawa, Hidenori Suzuki, Prativa Sherchan, Yan Zhan, Kamil Duris, John H Zhang
• Journal: Acta neurochirurgica. Supplement (Acta Neurochir Suppl) Vol. 110 Issue Pt 1 Pg. 67-70 ( 2011) ISSN: 0065-1419 [Print] Austria
• PMID: 21116917 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Vanadates
• Protein Tyrosine Phosphatases

Topics

• Animals
• Brain Edema (drug therapy, etiology)
• Brain Injuries (drug therapy, enzymology, etiology, mortality)
• Cell Death (drug effects)
• Disease Models, Animal
• In Situ Nick-End Labeling (methods)
• Male
• Neurologic Examination
• Protein Tyrosine Phosphatases (metabolism)
• Rats
• Rats, Sprague-Dawley
• Severity of Illness Index
• Subarachnoid Hemorrhage (complications)
• Time Factors
• Vanadates (therapeutic use)